NCT07292506Active, not recruiting
The Impact of Acupuncture on Biomarkers of Brain Injury and Inflammatory Response in Migraine
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
Migraine is more than just a headache-it can involve changes in the brain and inflammation. Recent research suggests that acupuncture may help by calming pain signals and reducing inflammation in the body. Scientists are studying whether acupuncture can also lower certain markers in the blood that show brain stress or inflammation. While more research is needed, acupuncture is considered safe and may reduce the number and severity of migraine attacks for many people. Acupuncture has been used for over 40 years in our practice to manage acute and chronic pain, including migraines. When performed by trained physicians, it is safe and typically reduces headache frequency and intensity, as well as nausea and vomiting, lowering the need for pain medication. Investigators are exploring three different ways to help manage migraine headaches using gentle stimulation techniques. These include laser acupuncture, electroacupuncture, and traditional acupuncture. Investigators want to see which method works best for reducing migraine symptoms. Investigators will look at how participants feel after treatment and also check blood samples for signs of inflammation and certain substances linked to migraines, such as calcitonin gene-related peptide (CGRP) and markers of brain stress. Investigators have a goal to find safe and effective options that can improve migraine care and help people feel better.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 3 Nov 2025
- Primary completion date
- 15 Mar 2026
- Lead sponsor
- University Medical Centre Ljubljana
- Diseases
- Migraine
- NCT number
- NCT07292506
What you commit to
- Study type: Interventional
- Planned participants: 75
- From 3 Nov 2025 to the primary completion date, 15 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Adults diagnosed with migraine headaches according to the International Classification of Headache Disorders (ICHD).
- Patients who are not currently receiving monoclonal antibodies targeting CGRP (Calcitonin Gene-Related Peptide)
- Ability to provide informed consent and comply with study procedures. Exclusion Criteria
- Use of CGRP monoclonal antibody therapy within the past 6 months.
- Other significant neurological or systemic conditions that could interfere with study outcomes.
- Pregnancy or breastfeeding.
Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical department of anaesthesiology and surgical intensive therapy University Medical Centre Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.